Novartis Will Co-Develop UCB’s Alpha-Syn Inhibitor For Parkinson’s

 
• By Joseph Haas
  
Scientists
Novartis and UCB will collaborate on a disease-modifying Parkinson's therapy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business